Simulated Digestion and Fermentation In Vitro by Obese Human Gut Microbiota of Sulforaphane from Broccoli Seeds

Multi-perspective analysis of skin microbiota in elderly eczema patients

Eczema is a common inflammatory skin disease in elderly people. It not only causes physical damage to elderly people but also seriously affects their mental health. The skin microbiota plays a vital role in the development of skin disease. However, relatively few studies have investigated the characteristics of the skin microbiota in elderly eczema patients. In this study, the differences in the composition of the skin microbiota between lesion sites and healthy sites, between exposed sites and unexposed sites, and between elderly and younger eczema sites were analyzed, aiming to characterize the skin microbiota in elderly eczema patients from multiple perspectives and provide a basis for clinical diagnosis and treatment. The results indicated that the species richness of elderly eczema patients was greater than that of younger eczema patients. There was no significant difference between groups at the phylum level. At the genus level, the abundance of Staphylococcus significantly increased in the lesion sites of the elderly group. Compared with the younger eczema group, the elderly eczema group had greater abundances of Paracoccus, Deinococcus_B, Kaistella, Escherichia_710834, and Chryseobacterium_796703. These findings indicated that more attention should be given to the roles of Kaistella and Streptococcus in elderly eczema patients because Kaistella was the only genus among the 20 most abundant genera that was closely related to the EASI scores. Moreover, correlation analysis suggested that many genera had a positive relationship with Streptococcus. The results provide basic microbiological data for physicians treating elderly patients with eczema.

Characterization of Myrosinase-Mediated Glucosinolate Degradation Pathways in Lactiplantibacillus plantarum ZUST49

Cruciferous vegetables are rich in glucosinolates that can be hydrolyzed by myrosinase into isothiocyanates (ITCs) with significant anticancer properties. In the absence of bacterial myrosinase, glucosinolates are excreted from the body in their inactive forms. However, the mechanisms underlying the bacterial breakdown of glucosinolates are not well understood. Here, we investigated the mechanism and enzymes involved in glucosinolate breakdown by the probiotic microorganism Lactiplantibacillus plantarum ZUST49, which degrades the glucosinolate glucoraphanin to sulforaphane and erucin. The glucoraphanin-degrading activity of this strain was induced by the presence of glucoraphanin and an absence of glucose. UPLC-MS analysis of the degradation products indicated that glucoraphanin was degraded via three distinct pathways, and further, transcriptomic and proteomic analyses led to the identification of a myrosinase gene, LpMyr, that encodes a 460-amino acid enzyme. The purified LpMyr protein exhibited optimal activity at 50 °C and pH 7.0, with hydrolysis rates of 7.74 U/mg for glucoraphanin and 5.89 U/mg for sinigrin. These findings provide new insights into the glucosinolate conversion capability of L. plantarum and highlight its potential for high-yield ITC production in the fermentation industry, as well as its potential use as a probiotic in the human gut.

Unveiling the microbiota-mediated impact of different dietary proteins on post-digestive processes: A simulated in vitro approach

Protein digestion and microbial metabolism play crucial roles in overall health. However, the mechanisms that differentiate the digestion and metabolism of dietary proteins from different sources in the organism remain poorly understood. This study investigated the digestive properties and microbial fermentation of various animal proteins (chicken, pork, beef, and casein) and plant proteins (soy bean, mung bean, kidney bean, rice, and wheat) in an in vitro simulation. The results indicated that animal-derived proteins had higher essential amino acid content (33.97-37.12 g/100 g) and digestibility levels (49.15-60.94 %), and provided more small molecule peptides upon digestion. Nevertheless, soy bean and wheat proteins also exhibited higher digestibility (54.70 % and 60.94 %), probably due to the extraction process. The fermentation results showed that distinct metabolic profiles that emerged for different protein sources. Plant-derived proteins (especially kidney bean, rice and wheat) promoted the proliferation of beneficial bacteria and microbial diversification and stimulated short-chain fatty acids (SCFA) production. Conversely, meat proteins (pork, chicken, beef) had significantly lower microbial diversity and SCFA than these plant proteins. These findings provide valuable insights into the effects of dietary protein sources on digestion and gut microbiome, and offer scientific guidance for optimizing dietary choices to improve health.

Bioactive sulforaphane from cruciferous vegetables: advances in biosynthesis, metabolism, bioavailability, delivery, health benefits, and applications

Chronic inflammation-induced diseases (CID) are the dominant cause of death worldwide, contributing to over half of all global deaths. Sulforaphane (SFN) derived from cruciferous vegetables has been extensively studied for its multiple functional benefits in alleviating CID. This work comprehensively reviewed the biosynthesis, metabolism, bioavailability, delivery, health benefits, and applications of SFN and its potential mechanisms against CID (e.g., cancer, obesity, type 2 diabetes, et al.), and neurological disorders based on a decade of research. SFN exerts its biological functions through the hydrolysis of glucosinolates by gut microbiota, and exhibits rapid metabolism and excretion characteristics via metabolization of mercapturic acid pathway. Microencapsulation is an important way to improve the stability and targeted delivery of SFN. The health benefits of SNF against CID are attributed to the multiple regulatory mechanisms including modulating oxidative stress, inflammation, apoptosis, immune response, and intestinal homeostasis. The clinical applications of SFN and related formulations show promising potential; however, further exploration is required regarding the sources, dosages, toxicity profiles, and stability of SFN. Together, SFN is a natural product with great potential for development and application, which is crucial for the development of functional food and pharmaceutical industries.

Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia

BACKGROUND

Polycystic ovary syndrome (PCOS) is an endocrinopathy in childbearing-age females which can cause many complications, such as diabetes, obesity, and dyslipidemia. The metabolic disorders in patients with PCOS were linked to gut microbial dysbiosis. However, the correlation between the gut microbial community and dyslipidemia in PCOS remains unillustrated. Our study elucidated the different gut microbiota in patients with PCOS and dyslipidemia (PCOS.D) compared to those with only PCOS and healthy women.

RESULTS

In total, 18 patients with PCOS, 16 healthy females, and 18 patients with PCOS.D were enrolled. The 16 S rRNA sequencing in V3-V4 region was utilized for identifying the gut microbiota, which analyzes species annotation, community diversity, and community functions. Our results showed that the β diversity of gut microbiota did not differ significantly among the three groups. Regarding gut microbiota dysbiosis, patients with PCOS showed a decreased abundance of Proteobacteria, and patients with PCOS.D showed an increased abundance of Bacteroidota compared to other groups. With respect to the gut microbial imbalance at genus level, the PCOS.D group showed a higher abundance of Clostridium_sensu_stricto_1 compared to other two groups. Furthermore, the abundances of Faecalibacterium and Holdemanella were lower in the PCOS.D than those in the PCOS group. Several genera, including Faecalibacterium and Holdemanella, were negatively correlated with the lipid profiles. Pseudomonas was negatively correlated with luteinizing hormone levels. Using PICRUSt analysis, the gut microbiota community functions suggested that certain metabolic pathways (e.g., amino acids, glycolysis, and lipid) were altered in PCOS.D patients as compared to those in PCOS patients.

CONCLUSIONS

The gut microbiota characterizations in patients with PCOS.D differ from those in patients with PCOS and controls, and those might also be related to clinical parameters. This may have the potential to become an alternative therapy to regulate the clinical lipid levels of patients with PCOS in the future.

Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells

Colorectal cancer (CRC) stands as a major cause of cancer-related mortality globally, accounting for approximately 881,000 deaths each year. Traditional approaches such as chemotherapy and surgery have been the primary treatment modalities, yet the outcomes for patients with metastatic CRC are often unsatisfactory. Recent research has focused on targeting the pathways involved in oxidative stress, inflammation, and metastasis to enhance the survival of CRC patients. Within this context, sulforaphane (SFN), a notable phytochemical found predominantly in cruciferous vegetables, has been recognized as a potential anticancer agent. However, the specific mechanisms through which SFN may exert its chemopreventive effects in CRC remain unclear. This study explores the impact of SFN on IL-1β-induced IL-6 activation and MAPK and AP-1 signaling in HT-29 cells. Our findings reveal that SFN treatment not only diminishes IL-1β-stimulated IL-6 expression but also reduces oxidative stress by curtailing reactive oxygen species (ROS) production. Furthermore, it hinders the proliferation and invasiveness of HT-29 cells through the modulation of MAPK/AP-1 and STAT3 signaling pathways. These results indicate that SFN mitigates IL-1β-induced IL-6 expression in CRC cells by attenuating ROS production and disrupting MAPK/AP-1 signaling. This suggests that SFN holds significant potential as a chemotherapeutic agent for both treating and preventing CRC.

The Regulatory Effect of Huangshui Polysaccharides on Intestinal Microbiota and Metabolites during In Vitro Fermentation

Huangshui polysaccharides (HSPs) have attracted extensive attention recently for their biological activity and physicochemical property. This research investigated the extraction, structural characterization, and prebiotic activity of three different HSPs (HSP40-0, HSP60-0, and HSP80-0) in vitro to reveal the scientific support for the high-value utilization of Huangshui. HSPs were heteropolysaccharide with diverse structures and surface morphologies. Comprehensive analysis was conducted through 16S rRNA gene sequencing and metabolite profiling techniques, and results showed that HSPs had different potentials to regulate the gut microbiota due to their different structures; for instance, both HSP40-0 and HSP80-0 could notably increase the relative abundance of Bacteroidota, whereas HSP60-0 could increase the relative abundance of Phascolarctobacterium. In addition, HSPs upregulated beneficial differential metabolites, especially short-chain fatty acids (SCFAs). Fermentation products containing these metabolites exhibited anti-inflammatory effects on LPS-treated Caco-2 cells. This study will provide reference for exploring the relationship between the natural polysaccharide structure and the prebiotic activity and widen the application of Huangshui.

In vitro fermentation characteristics of blueberry anthocyanins and their impacts on gut microbiota from obese human

It has been demonstrated that the gut microbiota may play an important intermediary role in anthocyanins' beneficial impacts on obesity. However, the microbe-related anti-obesity mechanism of blueberry anthocyanins remains unclear. In this study, the interactions between blueberry anthocyanin extracts (BAE) and gut microbiota from obese humans were explored using an in vitro fermentation model. Due to hydrolysis and metabolism by the microbiota, the contents of blueberry anthocyanins are reduced during fermentation. It was demonstrated that both aglycones and glycosides affected the degradation rate. The microbial composition evaluation revealed that BAE could alleviate obesity by promoting the colonization of probiotics such as Lachnospiraceae_UCG-004 and Bacteroides, as well as inhibiting the proliferation of harmful bacteria including Escherichia-Shigella, Clostridium_sensu_stricto_1, and Klebsiella. Blueberry anthocyanin extracts facilitate the production of short-chain fatty acids (SCFAs), which is beneficial for obesity control. The relationship between blueberry anthocyanins, gut microbiota, and SCFAs was further investigated. Overall, this data provides new insights into the positive interaction between blueberry anthocyanins and gut microbiota in obese humans.